Hyundai Pharmaceutical Co., Ltd. (KRX:004310)
12,720
-390 (-2.97%)
Feb 26, 2026, 11:20 AM KST
Hyundai Pharmaceutical Balance Sheet
Financials in millions KRW. Fiscal year is December - November.
Millions KRW. Fiscal year is Dec - Nov.
Fiscal Year | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 |
|---|---|---|---|---|---|
Period Ending | Nov '13 Nov 30, 2013 | Nov '12 Nov 30, 2012 | Nov '11 Nov 30, 2011 | Nov '10 Nov 30, 2010 | Nov '09 Nov 30, 2009 |
Cash & Equivalents | 14,087 | 16,267 | 13,629 | 11,320 | 7,531 |
Short-Term Investments | 543.24 | 343.24 | 343.24 | - | 120 |
Cash & Short-Term Investments | 14,630 | 16,610 | 13,972 | 11,320 | 7,651 |
Cash Growth | -11.92% | 18.88% | 23.43% | 47.95% | -41.97% |
Accounts Receivable | 42,522 | 43,050 | 53,981 | 50,842 | 53,108 |
Other Receivables | 2,239 | 2,271 | 1,987 | 1,563 | 1,970 |
Receivables | 44,762 | 45,320 | 55,969 | 52,405 | 55,078 |
Inventory | 20,971 | 24,100 | 17,058 | 14,026 | 16,015 |
Prepaid Expenses | 71.55 | 105.6 | 152.9 | 111.24 | 76.64 |
Other Current Assets | 42.24 | 38.25 | 357.93 | 74.29 | 208.4 |
Total Current Assets | 80,477 | 86,174 | 87,510 | 78,314 | 79,082 |
Property, Plant & Equipment | 33,346 | 33,097 | 40,726 | 43,167 | 46,320 |
Long-Term Investments | 5,832 | 5,474 | 3,797 | 7,320 | 6,948 |
Other Intangible Assets | 1,829 | 2,411 | 2,448 | 378.93 | 502.39 |
Other Long-Term Assets | 21,919 | 22,746 | 22,467 | 1,803 | 1,414 |
Total Assets | 143,403 | 149,903 | 156,948 | 130,982 | 134,268 |
Accounts Payable | 6,855 | 5,561 | 5,077 | 3,162 | 5,133 |
Accrued Expenses | 407.52 | 554.44 | 561.66 | 35.98 | 61.89 |
Short-Term Debt | 20,750 | 29,286 | 27,819 | 22,000 | 23,522 |
Current Income Taxes Payable | 58.94 | 315.93 | 1,113 | 678.22 | 54.94 |
Current Unearned Revenue | - | - | 6.75 | - | - |
Other Current Liabilities | 8,572 | 8,102 | 10,480 | 9,597 | 9,413 |
Total Current Liabilities | 36,644 | 43,820 | 45,057 | 35,473 | 38,185 |
Pension & Post-Retirement Benefits | 3,381 | 4,194 | 3,978 | 2,121 | 2,897 |
Long-Term Deferred Tax Liabilities | 1,932 | 2,126 | 3,597 | 882.5 | 588.19 |
Other Long-Term Liabilities | 234.02 | 75.6 | 0.32 | - | - |
Total Liabilities | 42,191 | 50,216 | 52,632 | 38,477 | 41,670 |
Common Stock | 14,000 | 14,000 | 14,000 | 14,000 | 14,000 |
Additional Paid-In Capital | 6,569 | 6,569 | 6,569 | 6,386 | 6,386 |
Retained Earnings | 75,362 | 74,236 | 80,230 | 68,406 | 66,662 |
Treasury Stock | -13,532 | -13,532 | -13,532 | -13,532 | -11,474 |
Comprehensive Income & Other | 18,307 | 17,953 | 16,590 | 17,245 | 17,024 |
Total Common Equity | 100,705 | 99,225 | 103,857 | 92,505 | 92,598 |
Minority Interest | 506.57 | 461.84 | 459.68 | - | - |
Shareholders' Equity | 101,212 | 99,687 | 104,316 | 92,505 | 92,598 |
Total Liabilities & Equity | 143,403 | 149,903 | 156,948 | 130,982 | 134,268 |
Total Debt | 20,750 | 29,286 | 27,819 | 22,000 | 23,522 |
Net Cash (Debt) | -6,120 | -12,676 | -13,847 | -10,680 | -15,871 |
Net Cash Per Share | -260.97 | -541.03 | -585.72 | -447.41 | -645.31 |
Filing Date Shares Outstanding | 23.45 | 23.45 | 23.45 | 23.45 | 24.48 |
Total Common Shares Outstanding | 23.45 | 23.45 | 23.45 | 23.45 | 24.48 |
Working Capital | 43,833 | 42,354 | 42,453 | 42,840 | 40,898 |
Book Value Per Share | 4294.60 | 4231.46 | 4428.99 | 3944.89 | 3782.43 |
Tangible Book Value | 98,877 | 96,814 | 101,409 | 92,126 | 92,096 |
Tangible Book Value Per Share | 4216.61 | 4128.64 | 4324.59 | 3928.73 | 3761.91 |
Land | 18,743 | 17,818 | 24,546 | 22,567 | 25,917 |
Buildings | 19,464 | 19,365 | 19,388 | 18,629 | 20,272 |
Machinery | 17,480 | 16,418 | 16,311 | 15,901 | 15,059 |
Construction In Progress | 701.51 | 779.93 | 206.76 | 6,520 | 4,350 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.